关于上海金畔生物科技有限公司

jinpanbio

Rituximab(Synonyms: 利妥昔单抗; Anti-Human CD20 type I, Chimeric Antibody)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Rituximab (Synonyms: 利妥昔单抗; Anti-Human CD20 type I, Chimeric Antibody) 纯度: 98.42%

Rituximab 是一种抗 CD20 嵌合单克隆抗体,用于某些自身免疫疾病和癌症的研究。

Rituximab(Synonyms: 利妥昔单抗; Anti-Human CD20 type I, Chimeric Antibody)

Rituximab Chemical Structure

CAS No. : 174722-31-7

规格 价格 是否有货 数量
1 mg ¥2800 In-stock
5 mg ¥5600 In-stock
25 mg 询价
50 mg 询价

* Please select Quantity before adding items.

生物活性

Rituximab is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer.

体外研究
(In Vitro)

Rituximab inhibits the proliferation of stimulated human B cells, which is associated with a relative increase of B cells with an activated naive phenotype. Aside from this population shift, there are no major changes in phenotype or cytokine profile of the various B-cell subsets. B cells stimulated in the presence of rituximab induces stronger T-cell proliferation, compared to B cells stimulated in the absence of rituximab[1]. All lymphoma cells tested are equally sensitive to antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-mediated phagocytosis of tumor cells, and rituximab-induced apoptosis. Rituximab induces high CDC killing of follicular lymphoma cells[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

A single injection of rituximab or the murine anti-CD20 Ab 1F5, given i.p. 1 day after the tumor, cures 100% of the animals. Depletion of either NK cells or neutrophils or both in tumor-injected animals does not affect the therapeutic activity of the drug. Similarly, rituximab is able to eradicate tumor cells in athymic nude mice, suggesting that its activity is T cell independent[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

144544.44

CAS 号

174722-31-7

中文名称

利妥昔单抗

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Kamburova EG, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant. 2012 Feb;12(2):341-50.

    [2]. Manches O, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003 Feb 1;101(3):949-54.

    [3]. Byrd JC, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002 Feb 1;99(3):1038-43.

Cell Assay

A single injection of rituximab or the murine anti-CD20 Ab 1F5, given i.p. 1 day after the tumor, cures 100% of the animals. Depletion of either NK cells or neutrophils or both in tumor-injected animals does not affect the therapeutic activity of the drug. Similarly, rituximab is able to eradicate tumor cells in athymic nude mice, suggesting that its activity is T cell independent[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[1]

C57BL/6 mice (8-10 wk of age) are inoculated 8×103 EL4-CD20+ cells in 200 μL of saline by tail vein injection. In parallel groups of mice, 150 g of rituximab, murine anti-CD20 IgG2a Ab 1F5, or control anti-human IL-2R Ab daclizumab in 300 μL of saline, or saline only is inoculated i.p. 24 h later[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Kamburova EG, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant. 2012 Feb;12(2):341-50.

    [2]. Manches O, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003 Feb 1;101(3):949-54.

    [3]. Byrd JC, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002 Feb 1;99(3):1038-43.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

超声波清洗器KQ-500B/KQ-500E/KQ-500V

【简单介绍】

超声波清洗器KQ-500B/KQ-500E/KQ-500V/KQ-500采用电路自动扫频技术,使清洗机工作电功率转换更高,无功损耗更低,大大提升了清洗的洁净度,可满足各行业实验室的超声清洗等需求。主要适用于商业、轻工、大专院校、科研单位的小批量清洗、脱气、消泡、乳化、混匀、置换、提取、粉料粉碎及细胞粉碎。

【详细说明】

台式超声波清洗器KQ-500B/KQ-500E/KQ-500V/KQ-500

产品简述:

  台式超声波清洗机,采用电路自动扫频技术,使清洗机工作电功率转换更高,无功损耗更低,大大提升了清洗的洁净度,可满足各行业实验室的超声清洗等需求。主要适用于商业、轻工、大专院校、科研单位的小批量清洗、脱气、消泡、乳化、混匀、置换、提取、粉料粉碎及细胞粉碎.

超声波清洗器KQ-500B/KQ-500E/KQ-500V/KQ-500

主要性能及特点

  1. 经典机械式控制,操作简单方便
  2. 清洗机降音盖、清洗槽均采用优质不锈钢
  3. 清洗机电路具有自动扫频功能,能产生连续脉冲射流,使清洗效果更明显,工作更稳定
  4. 清洗机电路及器件升级并匹配,电功转换率高、无功损耗低
  5. 可选单种超声频率有20KHz、25KHz、28KHz、33KHz、40KHz。

/KQ-500

技术参数:

型号:KQ-500 外形尺寸:530*320*368mm 内槽尺寸:500*300*150mm 容量:22.5L
标准超声频率:40KHz 超声频率可选择替换 频率转换时间可调:— 超声功率:500W
超声功率可调范围:— 水位显示:— 加热功率:—  
制冷功率:— 温度设定范围:— 工作时间可调:1-20min 溶液过滤:—
其他配置:清洗网篮、手控进排水、220V/50Hz电源
型号:KQ-500B 外形尺寸:530*320*368mm 内槽尺寸:500*300*150mm 容量:22.5L
标准超声频率:40KHz 超声频率可选择替换 频率转换时间可调:— 超声功率:500W
超声功率可调范围:— 水位显示:— 加热功率:1000W  
制冷功率:— 温度设定范围:室温-80℃ 工作时间可调:1-20min 溶液过滤:—
其他配置:清洗网篮、手控进排水、220V/50Hz电源
型号:KQ-500E 外形尺寸:530*320*383mm 内槽尺寸:500*300*150mm 容量:22.5L
标准超声频率:40KHz 超声频率可选择替换 频率转换时间可调:— 超声功率:500W
超声功率可调范围:— 水位显示:— 加热功率:1000W  
制冷功率:— 温度设定范围:室温-80℃ 工作时间可调:1-20min 溶液过滤:—
其他配置:清洗网篮、降音盖、手控进排水、220V/50Hz电源
型号:KQ-500V 外形尺寸:610*410*385mm 内槽尺寸:500*300*180mm 容量:27L
标准超声频率:40KHz 超声频率可选择替换 频率转换时间可调:— 超声功率:500W
超声功率可调范围:— 水位显示:— 加热功率:1000W  
制冷功率:— 温度设定范围:室温-80℃ 工作时间可调:1-20min 溶液过滤:—
其他配置:清洗网篮、降音盖、手控进排水、220V/50Hz电源

/KQ-500

Darifenacin hydrobromide(Synonyms: 氢溴酸达非那新; UK-88525 hydrobromide)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Darifenacin hydrobromide (Synonyms: 氢溴酸达非那新; UK-88525 hydrobromide) 纯度: 98.28%

Darifenacin hydrobromide (UK-88525 hydrobromide) 是选择性 M3 蕈毒碱受体拮抗剂,pKi 为 8.9。

Darifenacin hydrobromide(Synonyms: 氢溴酸达非那新; UK-88525 hydrobromide)

Darifenacin hydrobromide Chemical Structure

CAS No. : 133099-07-7

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥605 In-stock
10 mg ¥550 In-stock
100 mg ¥2750 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Darifenacin hydrobromide 相关产品

相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • GPCR/G Protein Compound Library
  • Neuronal Signaling Compound Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Drug Repurposing Compound Library
  • Orally Active Compound Library
  • Neurotransmitter Receptor Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Drug-Induced Liver Injury (DILI) Compound Library
  • Anti-Parkinson’s Disease Compound Library
  • Neurodegenerative Disease-related Compound Library
  • Rare Diseases Drug Library

生物活性

Darifenacin hydrobromide (UK-88525 hydrobromide) is a selective M3 muscarinic receptor antagonist with pKi of 8.9. IC50 value: 8.9 (pKi) [1] Target: M3 receptor in vitro: Darifenacin exerts non-parallel rightward displacement of the agonist curve and also significant depression of the maximum response (+)-cis-Dioxolane produced concentration-dependent contraction of the isolated bladder of rat [1]. Darifenacin produces a concentration dependent increase in R123 (P-gp probe) accumulation in MDCK cells. Darifenacin stimulates ATPase activity in P-gp membrane in a clear concentration dependent response manner with an estimated ED50 value of 1.6 μM. Darifenacin (100 nM) shows a significantly greater permeability for darifenacin in the basolateral to apical direction resulting in an efflux ratio in BBMEC monolayers of approximately 2.6 [2]. in vivo: Darifenacin produces dose-dependent inhibition of amplitude of volume-induced bladder contractions(VIBCAMP), producing 35% inhibition at dose of 283.3 nmol/kg and maximal inhibition of approximately 50–55% [1]. Darifenacin (0.1 mg/kg i.v.) reduces bladder afferent activity in both Aδ and C fibers in female Sprague-Dawley rats, the decrease in afferent spikes in C fibers may be more pronounced than that in Aδ fibers [3].

Clinical Trial

分子量

507.46

Formula

C28H31BrN2O2

CAS 号

133099-07-7

中文名称

氢溴酸达非那新;氢溴酸达菲那新

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro: 

DMSO : 33.33 mg/mL (65.68 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.9706 mL 9.8530 mL 19.7060 mL
5 mM 0.3941 mL 1.9706 mL 3.9412 mL
10 mM 0.1971 mL 0.9853 mL 1.9706 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (4.93 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.93 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (4.93 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.93 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (4.93 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.93 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Hegde SS, et al. Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol, 1997, 120(8), 1409-1418.

    [2]. Miller DW, et al. Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models of the blood-brain and blood-ocular barriers. Neurourol Urodyn, 2011, 30(8), 1633-1638.

    [3]. Iijima K, et al. Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol, 2007, 52(3), 842-847.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Dihydroguaiaretic acid

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Dihydroguaiaretic acid  纯度: 98.86%

Dihydroguaiaretic acid,从五味子的果实中分离,具有抗癌活性。

Dihydroguaiaretic acid

Dihydroguaiaretic acid Chemical Structure

CAS No. : 66322-34-7

规格 价格 是否有货 数量
1 mg ¥1900 In-stock
5 mg ¥5710 In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

Dihydroguaiaretic acid 相关产品

相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Natural Product Library
  • Anti-Cancer Compound Library
  • Phenols Library
  • Traditional Chinese Medicine Monomer Library

生物活性

Dihydroguaiaretic acid, is isolated from the fruits of Schisandra chinensis with an anti-cancer activty[1].

体外研究
(In Vitro)

Dihydroguaiaretic acid shows inhibitory effect on Human ovarian cancer cells and A2780 Human endometrial cancer cells Ishikawa with IC50 values of 27.17 μM and 45.46 μM, respectively[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

330.42

Formula

C20H26O4

CAS 号

66322-34-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

参考文献
  • [1]. Arch Pharm Res. 2017 Apr;40(4):500-508. doi: 10.1007/s12272-017-0902-5. Epub 2017 Feb 22.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

ent-16β,17-Dihydroxykauran-19-oic acid对照品

ent-16β,17-Dihydroxykauran-19-oic acid对照品

  【编号】:SPR00718

  【产品名称】:ent-16β,17-Dihydroxykauran-19-oic acid对照品

  【规格】:10mg

  【用途】:

  ent-16β,17-Dihydroxykauran-19-oic acid对照品

  编号:SPR00718
  英文名称:ent-16β,17-Dihydroxykauran-19-oic acid
  CAS No.:3301-61-9
  分 子 式:C20H32O4
  分 子 量:336.472
  类别:上海金畔生物科技有限公司,天然提取物
  作为标准品,对照品或者供研究用,不能直接用于人体。

Linsitinib(Synonyms: OSI-906)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Linsitinib (Synonyms: OSI-906) 纯度: 99.88%

Linsitinib (OSI-906) 是一种有效选择性的,具有口服活性的 IGF-1 和胰岛素受体 (IR) 的双重抑制剂,IC50 分别为 35 和 75 nM。

Linsitinib(Synonyms: OSI-906)

Linsitinib Chemical Structure

CAS No. : 867160-71-2

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥1020 In-stock
2 mg ¥750 In-stock
5 mg ¥1100 In-stock
10 mg ¥1850 In-stock
50 mg ¥4700 In-stock
100 mg ¥8100 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Linsitinib 相关产品

相关化合物库:

  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Kinase Inhibitor Library
  • Protein Tyrosine Kinase Compound Library
  • Anti-Cancer Compound Library
  • Clinical Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Differentiation Inducing Compound Library
  • Diabetes Related Compound Library
  • Endocrinology Compound Library
  • Anti-COVID-19 Compound Library
  • Orally Active Compound Library
  • Chemical Probe Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Angiogenesis Related Compound Library
  • Rare Diseases Drug Library

生物活性

Linsitinib (OSI-906) is a potent, selective and orally bioavailable dual inhibitor of the IGF-1 receptor and insulin receptor (IR) with IC50s of 35 and 75 nM, respectively[1].

IC50 & Target

IC50: 35 nM (IGF-1R), 75 nM (InsR)[1]

体外研究
(In Vitro)

Linsitinib inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. Linsitinib enables an intermediate conformation of the target protein through interactions with the C-helix. Linsitinib displays favorable metabolic stability in liver microsomes. Linsitinib fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. Linsitinib inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Linsitinib inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. Linsitinib administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. Linsitinib administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to Linsitinib dose. Linsitinib elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. Linsitinib administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM[1]. Linsitinib administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. Linsitinib inhibits the growth of tumors in NCI-H292 xenograft mouse model[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

421.49

Formula

C26H23N5O

CAS 号

867160-71-2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (118.63 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.3725 mL 11.8627 mL 23.7254 mL
5 mM 0.4745 mL 2.3725 mL 4.7451 mL
10 mM 0.2373 mL 1.1863 mL 2.3725 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 30% Solutol HS-15

    Solubility: 5 mg/mL (11.86 mM); Suspended solution; Need ultrasonic

  • 2.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (5.93 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.93 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 3.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (5.93 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.93 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Mulvihill MJ, et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and IR. Future Med Chem. 2009 Sep;1(6):1153-71.

    [2]. McKinley ET, et al. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Clin Cancer Res. 2011 May 15;17(10):3332-40.

    [3]. Li W, et al. Effectiveness of inhibitor rapamycin, saracatinib, linsitinib and JNJ-38877605 against human prostate cancer cells. Int J Clin Exp Med. 2015 Apr 15;8(4):6563-7.

Kinase Assay
[1]

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405/490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose-response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. Linsitinib at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay
[1]

For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of Linsitinib at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of Linsitinib by the cellular density of control cells treated with vehicle (DMSO) only.

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[1]

Cells are harvested from cell culture flasks during exponential cell growth, washed twice with sterile PBS to a suitable concentration before subcutaneous implantation on the right flank of female nu/nu CD-1 mice. Tumors are established to 200±50 mm3 in size before randomization into treatment groups of eight mice each for efficacy studies. Linsitinib or vehicle is administered orally as indicated. The %TGI values indicated are the median %TGI over the entire dosing period. TGI of at lease 505 is considered significant. Growth delay is calculated as T-C shere T and C are the times in days for mean tumor size in the treated (T) and control (C) groups to reach 400% of the initial tumor volume. Cures are excluded from this calculation.

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Mulvihill MJ, et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and IR. Future Med Chem. 2009 Sep;1(6):1153-71.

    [2]. McKinley ET, et al. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Clin Cancer Res. 2011 May 15;17(10):3332-40.

    [3]. Li W, et al. Effectiveness of inhibitor rapamycin, saracatinib, linsitinib and JNJ-38877605 against human prostate cancer cells. Int J Clin Exp Med. 2015 Apr 15;8(4):6563-7.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

PP121

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

PP121  纯度: 99.08%

PP121是多靶点激酶抑制剂,抑制 mTORDNK-PKVEGFR2SrcPDGFRIC50 值分别为10,60,12,14,2 nM。

PP121

PP121 Chemical Structure

CAS No. : 1092788-83-4

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥921 In-stock
10 mg ¥837 In-stock
50 mg ¥2976 In-stock
100 mg ¥3950 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

PP121 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Kinase Inhibitor Library
  • PI3K/Akt/mTOR Compound Library
  • Protein Tyrosine Kinase Compound Library
  • Stem Cell Signaling Compound Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Anti-Aging Compound Library
  • Antioxidants Compound Library
  • Differentiation Inducing Compound Library
  • Reprogramming Compound Library
  • Oxygen Sensing Compound Library
  • Glycolysis Compound Library
  • Cytoskeleton Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Cancer Metabolism Compound Library
  • Angiogenesis Related Compound Library
  • Glucose Metabolism Compound Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

PP121 is a multi-targeted kinase inhibitor with IC50s of 10, 60, 12, 14, 2 nM for mTOR, DNK-PK, VEGFR2, Src, PDGFR, respectively.

IC50 & Target[1]

VEGFR2

12 nM (IC50)

PDGFR

2 nM (IC50)

mTOR

10 nM (IC50)

DNK-PK

60 nM (IC50)

Src

14 nM (IC50)

体外研究
(In Vitro)

PP121 blocks the PI3K pathway by direct inhibition of PI3K/mTOR in two glioblastoma cell lines, U87 and LN229. PP121 potently inhibits the proliferation of a diverse panel of tumor cell lines containing mutations in the PI3-K pathway components PIK3CA, PTEN, or RAS. PP121 induces a G0G1 arrest in most tumor cells. PP121 directly inhibits Src in cells and reverses its biochemical and morphological effects. PP121 potently inhibits the Ret kinase domain in vitro (IC50<1 nm). pp121 potently blocks vegf stimulated activation of the pi3-k and mapk pathways. inhibits vegfr2 autophosphorylation at low nanomolar concentrations, confirming that this molecule directly targets in cells. bcr-abl induced tyrosine phosphorylation k562 cells as well baf3 express bcr-abl[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Oral administration of PP121 remarkably inhibits Eca-109 xenograft growth. Mice body weights are not significantly affected by PP121 or the vehicle treatment. PP121 oral administration dramatically inhibits activations of Akt-mTOR and NFkB in xenograft tumors. p-Akt Ser 473 and p-IKKa/b are both inhibited by PP121 administration[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

319.36

Formula

C17H17N7

CAS 号

1092788-83-4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 20 mg/mL (62.63 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.1313 mL 15.6563 mL 31.3126 mL
5 mM 0.6263 mL 3.1313 mL 6.2625 mL
10 mM 0.3131 mL 1.5656 mL 3.1313 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2 mg/mL (6.26 mM); Clear solution

    此方案可获得 ≥ 2 mg/mL (6.26 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2 mg/mL (6.26 mM); Clear solution

    此方案可获得 ≥ 2 mg/mL (6.26 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2 mg/mL (6.26 mM); Clear solution

    此方案可获得 ≥ 2 mg/mL (6.26 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Apsel B, et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol, 2008, 4(11), 691-699.

    [2]. Peng Y, et al. The anti-esophageal cancer cell activity by a novel tyrosine/phosphoinositide kinase inhibitor PP121. Biochem Biophys Res Commun. 2015 Sep 11;465(1):137-44.

Kinase Assay
[1]

Purified kinase domains are incubated with inhibitors (PP121) at 2- or 4-fold dilutions over a concentration range of 50- 0.001 µM or with vehicle (0.1% DMSO) in the presence of 10 µM ATP, 2.5 µCi of γ- 32P-ATP and substrate. Reactions are terminated by spotting onto nitrocellulose or phosphocellulose membranes, depending on the substrate; this membrane is then washed 5-6 times to remove unbound radioactivity and dried. Transferred radioactivity is quantitated by phosphorimaging and IC50 values are calculated by fitting the data to a sigmoidal doseresponse using Prism software[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay

Cells grown in 96-well plates are treated with PP121 at 4-fold dilutions (10 µM – 0.040 μM) or vehicle (0.1% DMSO). After 72 h cells are exposed to Resazurin sodium salt (22 µM) and fluorescence is quantified. IC50 values are calculated. For proliferation assays involving single cell counting, non-adherent cells are plated at low density (3–5% confluence) and treated with drug (2.5 µM) or vehicle (0.1% DMSO). Cells are diluted into trypan blue daily and viable cells counted using a hemocytometer[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[2]

Mice: Eca-109 cells are injected into the axillary regions of nude mice (5×106 cells/mouse). When the tumor volumes reach around 200 mm3, the mice are randomly separated to three groups: Untreated control, PP121 (30 mg/kg) and vehicle (10% 1-methyl-2-pyrrolidinone and 90% PEG 300) group. Tumor volumes and the mice body weights are measured every 10 d[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Apsel B, et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol, 2008, 4(11), 691-699.

    [2]. Peng Y, et al. The anti-esophageal cancer cell activity by a novel tyrosine/phosphoinositide kinase inhibitor PP121. Biochem Biophys Res Commun. 2015 Sep 11;465(1):137-44.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

10L超声波清洗器KQ-250B/KQ-250E/KQ-250V

【简单介绍】

10L超声波清洗器KQ-250B/KQ-250E/KQ-250V/KQ-250采用电路自动扫频技术,使清洗机工作电功率转换更高,无功损耗更低,大大提升了清洗的洁净度,可满足各行业实验室的超声清洗等需求。主要适用于商业、轻工、大专院校、科研单位的小批量清洗、脱气、消泡、乳化、混匀、置换、提取、粉料粉碎及细胞粉碎.

【详细说明】

10L超声波清洗器KQ-250B/KQ-250E/KQ-250V/KQ-250

产品简述:

   台式超声波清洗机,采用电路自动扫频技术,使清洗机工作电功率转换更高,无功损耗更低,大大提升了清洗的洁净度,可满足各行业实验室的超声清洗等需求。

   可用于:超声波清洗、乳化、混匀、提取、分散、消泡、脱气、细胞粉碎、催化反应等

主要性能特点

  1. 经典机械式控制,操作简单方便
  2. 清洗机降音盖、清洗槽均采用优质不锈钢
  3. 可选单种超声频率有20KHz、25KHz、28KHz、33KHz、40KHz
  4. 清洗机电路具有自动扫频功能,能产生连续脉冲射流,使清洗效果更明显,工作更稳定
  5. 清洗机电路及器件升级并匹配,电功转换率高、无功损耗低

10L超声波清洗器KQ-250B/KQ-250E/KQ-250V/KQ-250

技术规格:

型号:KQ-250 外形尺寸:320*264*320mm 内槽尺寸:300*240*150mm 容量:10L
标准超声频率:40KHz 超声频率可选择替换 频率转换时间可调:— 超声功率:250W
超声功率可调范围:— 水位显示:— 加热功率:—  
制冷功率:— 温度设定范围:— 工作时间可调:1-20min 溶液过滤:—
其他配置:清洗网篮、手控进排水、220V/50Hz电源
型号:KQ-250B 外形尺寸:320*264*320mm 内槽尺寸:300*240*150mm 容量:10L
标准超声频率:40KHz 超声频率可选择替换 频率转换时间可调:— 超声功率:250W
超声功率可调范围:— 水位显示:— 加热功率:600W  
制冷功率:— 温度设定范围:室温-80℃ 工作时间可调:1-20min 溶液过滤:—
其他配置:清洗网篮、手控进排水、220V/50Hz电源
型号:KQ-250E 外形尺寸:320*264*335mm 内槽尺寸:300*240*150mm 容量:10L
标准超声频率:40KHz 超声频率可选择替换 频率转换时间可调:— 超声功率:250W
超声功率可调范围:— 水位显示:— 加热功率:600W  
制冷功率:— 温度设定范围:室温-80℃ 工作时间可调:1-20min 溶液过滤:—
其他配置:清洗网篮、降音盖、手控进排水、220V/50Hz电源
型号:KQ-250V 外形尺寸:445*347*390mm 内槽尺寸:300*240*180mm 容量:13L
标准超声频率:40KHz 超声频率可选择替换 频率转换时间可调:— 超声功率:250W
超声功率可调范围:— 水位显示:— 加热功率:600W  
制冷功率:— 温度设定范围:室温-80℃ 工作时间可调:1-20min 溶液过滤:—
其他配置:清洗网篮、降音盖、手控进排水、220V/50Hz电源

 /KQ-250

Acetamide(Synonyms: 乙酰胺)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Acetamide (Synonyms: 乙酰胺) 纯度: ≥98.0%

Acetamide 是合成甲胺,硫代乙酰胺和杀虫剂中间体,也用作皮革,布料和涂料中的增塑剂。 Acetamide 具有致癌性。

Acetamide(Synonyms: 乙酰胺)

Acetamide Chemical Structure

CAS No. : 60-35-5

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in Water ¥550 In-stock
5 g ¥500 In-stock
10 g   询价  
50 g   询价  

* Please select Quantity before adding items.

Acetamide 相关产品

相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Natural Product Library
  • Anti-Cancer Compound Library
  • Fragment Library
  • FDA Approved & Pharmacopeial Drug Library
  • Food Additive Library
  • Food-Sourced Compound Library
  • Tumorigenesis Related Compound Library
  • Rare Diseases Drug Library

生物活性

Acetamide is used as an intermediate in the synthesis of methylamine, thioacetamide, and insecticides, and as a plasticizer in leather, cloth and coatings. Acetamide has carcinogenicity[1][2].

IC50 & Target

Human Endogenous Metabolite

 

分子量

59.07

Formula

C2H5NO

CAS 号

60-35-5

中文名称

乙酰胺

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

H2O : 50 mg/mL (846.45 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 16.9291 mL 84.6453 mL 169.2907 mL
5 mM 3.3858 mL 16.9291 mL 33.8581 mL
10 mM 1.6929 mL 8.4645 mL 16.9291 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

参考文献
  • [1]. Acetamide. IARC Monogr Eval Carcinog Risks Hum. 1999;71 Pt 3:1211-21.

    [2]. Moore MM, et, al. The food contaminant acetamide is not an in vivo clastogen, aneugen, or mutagen in rodent hematopoietic tissue. Regul Toxicol Pharmacol. 2019 Nov;108:104451.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

3-软脂酸赤二醇酯对照品

3-软脂酸赤二醇酯对照品

  【编号】:SPR00682

  【产品名称】:3-软脂酸赤二醇酯对照品

  【规格】:10mg

  【用途】:

  3-软脂酸赤二醇酯对照品

  编号:SPR00682
  英文名称:Erythrodiol 3-palmitate
  CAS No.:19833-13-7
  分 子 式:C46H80O3
  分 子 量:681.143
  类别:上海金畔生物科技有限公司,天然提取物
  作为标准品,对照品或者供研究用,不能直接用于人体。

Geldanamycin(Synonyms: 格尔德霉素)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Geldanamycin (Synonyms: 格尔德霉素) 纯度: 99.78%

Geldanamycin是 Hsp90 抑制剂,具有抗许多革兰氏阳性和一些革兰氏阴性细菌的活性。Geldanamycin 还具有抗流感病毒 H5N1 的活性。

Geldanamycin(Synonyms: 格尔德霉素)

Geldanamycin Chemical Structure

CAS No. : 30562-34-6

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥1544 In-stock
5 mg ¥1252 In-stock
10 mg ¥1989 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Geldanamycin 相关产品

相关化合物库:

  • Covalent Screening Library Plus
  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Anti-Infection Compound Library
  • Cell Cycle/DNA Damage Compound Library
  • Immunology/Inflammation Compound Library
  • Metabolism/Protease Compound Library
  • Natural Product Library
  • Anti-Cancer Compound Library
  • Antiviral Compound Library
  • Anti-Aging Compound Library
  • Covalent Screening Library
  • Antibacterial Compound Library
  • Endoplasmic Reticulum Stress Compound Library
  • Pyroptosis Compound Library
  • Cytoskeleton Compound Library
  • Antibiotics Library
  • Microbial Metabolite Library

生物活性

Geldanamycin is a Hsp90 inhibitor with antimicrobial activity against many Gram-positive and some Gram-negative bacteria. Geldanamycin has anti-influenza virus H5N1 activities.

IC50 & Target

HSP90

1.2 μM (Kd)

体外研究
(In Vitro)

Geldanamycin significantly delays and reduces viperin expression, indicating that IRF3 is involved in viperin induction in RAW264.7 cells[1]. Geldanamycin (GA), a benzoquinone ansamycin, protected against neuronal injury induced by oxygen-glucose deprivation (OGD)/zVAD treatment in cultured primary neurons. More importantly, Geldanamycin decreases RIP1 protein level in a time and concentration-dependent manner. Geldanamycin also decreases the Hsp90 protein level, which causes instability of RIP1 protein, resulting in decreased RIP1 protein level but not RIP1 mRNA level after Geldanamycin treatment[2]. Geldanamycin (GA) is identified as the first natural product inhibitor of Hsp90 that binds to the N-terminal ATPase domain of Hsp90 to inhibit its chaperone function, and significantly induces tumor cell death via an apoptotic mechanism[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

560.64

Formula

C29H40N2O9

CAS 号

30562-34-6

中文名称

格尔德霉素

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (89.18 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.7837 mL 8.9184 mL 17.8368 mL
5 mM 0.3567 mL 1.7837 mL 3.5674 mL
10 mM 0.1784 mL 0.8918 mL 1.7837 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: 2.5 mg/mL (4.46 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.5 mg/mL (4.46 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (4.46 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.5 mg/mL (4.46 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Tang HB, et al. Viperin inhibits rabies virus replication via reduced cholesterol and sphingomyelin and is regulated upstream by TLR4. Sci Rep. 2016 Jul 26;6:30529

    [2]. Chen WW, et al. RIP1 mediates the protection of Geldanamycin on neuronal injury induced by oxygen-glucosedeprivation combined with zVAD in primary cortical neurons. J Neurochem. 2012 Jan;120(1):70-7.

    [3]. Lin Z, et al. 17-ABAG, a novel Geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition. Int J Mol Med. 2015 Aug;36(2):424-32.

    [4]. Roe SM, et al. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem. 1999 Jan 28;42(2):260-6.

    [5]. Wang C, et al. Geldanamycin Reduces Acute Respiratory Distress Syndrome and Promotes the Survival of Mice Infected with the Highly Virulent H5N1 Influenza Virus. Front Cell Infect Microbiol. 2017 Jun 15;7:267.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

6L超声波清洗器KQ3200B/KQ3200E/KQ3200V

【简单介绍】

6L超声波清洗器KQ3200B/KQ3200E/KQ3200V/KQ3200,采用电路自动扫频技术,使清洗机工作电功率转换更高,无功损耗更低,大大提升了清洗的洁净度,可满足各行业实验室的超声清洗等需求。
系列产品可用于:超声波清洗、乳化、混匀、提取、分散、消泡、脱气、细胞粉碎、催化反应等

【详细说明】

6L超声波清洗器KQ3200B/KQ3200E/KQ3200V/KQ3200

产品简述:

  采用电路自动扫频技术,使清洗机工作电功率转换更高,无功损耗更低,大大提升了清洗的洁净度,可满足各行业实验室的超声清洗等需求。

  系列产品可用于:超声波清洗、乳化、混匀、提取、分散、消泡、脱气、细胞粉碎、催化反应等

主要性能及特点

  • 经典机械式控制,操作简单方便
  • 清洗机降音盖、清洗槽均采用优质不锈钢
  • 清洗机电路具有自动扫频功能,能产生连续脉冲射流,使清洗效果更明显,工作更稳定
  • 清洗机电路及器件升级并匹配,电功转换率高、无功损耗低
  • 可选单种超声频率有20KHz、25KHz、28KHz、33KHz、40KHz

6L超声波清洗器KQ3200B/KQ3200E/KQ3200V/KQ3200

技术参数:

型号:KQ3200 外形尺寸:320*174*320mm 内槽尺寸:300*150*150mm 容量:6L
标准超声频率:40KHz 超声频率可选择替换 频率转换时间可调:— 超声功率:150W
超声功率可调范围:— 水位显示:— 加热功率:—  
制冷功率:— 温度设定范围:— 工作时间可调:1-20min 溶液过滤:—
其他配置:清洗网篮、手控进排水、220V/50Hz电源
型号:KQ3200B 外形尺寸:320*174*320mm 内槽尺寸:300*150*150mm 容量:6L
标准超声频率:40KHz 超声频率可选择替换 频率转换时间可调:— 超声功率:150W
超声功率可调范围:— 水位显示:— 加热功率:400W  
制冷功率:— 温度设定范围:室温-80℃ 工作时间可调:1-20min 溶液过滤:—
其他配置:清洗网篮、手控进排水、220V/50Hz电源
型号:KQ3200E 外形尺寸:320*174*335mm 内槽尺寸:300*150*150mm 容量:6L
标准超声频率:40KHz 超声频率可选择替换 频率转换时间可调:— 超声功率:150W
超声功率可调范围:— 水位显示:— 加热功率:400W  
制冷功率:— 温度设定范围:室温-80℃ 工作时间可调:1-20min 溶液过滤:—
其他配置:清洗网篮、降音盖、手控进排水、220V/50Hz电源
型号:KQ3200V 外形尺寸:410*260*380mm 内槽尺寸:300*150*180mm 容量:8L
标准超声频率:40KHz 超声频率可选择替换 频率转换时间可调:— 超声功率:150W
超声功率可调范围:— 水位显示:— 加热功率:400W  
制冷功率:— 温度设定范围:室温-80℃ 工作时间可调:1-20min 溶液过滤:—
其他配置:清洗网篮、降音盖、手控进排水、220V/50Hz电源

/KQ3200

相关产品:

KQ3200超声波清洗器

容量(L):6, 超声频率(KHz):40, 超声功率:150W

 

KQ3200B超声波清洗器

容量(L):6, 超声频率(KHz):40, 超声功率:150W

无盖 

KQ3200E超声波清洗器

容量(L):6, 超声频率(KHz):40, 超声功率:150W

 

KQ3200V超声波清洗器

容量(L):8, 超声频率(KHz):40, 超声功率:150W

 

/KQ3200

 

(-)-Epigallocatechin-3-(3”-O-methyl) gallate(Synonyms: (-)-EGCG-3”-O-ME)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

(-)-Epigallocatechin-3-(3”-O-methyl) gallate (Synonyms: (-)-EGCG-3”-O-ME) 纯度: ≥99.0%

(-)-Epigallocatechin-3-(3”-O-methyl) gallate 是从茶叶中分离出的一种天然产物,具有很强的抗氧化和细胞毒性。(-)-Epigallocatechin-3-(3”-O-methyl) gallate 对大鼠癌细胞具有较强的细胞毒性。

(-)-Epigallocatechin-3-(3

(-)-Epigallocatechin-3-(3”-O-methyl) gallate Chemical Structure

CAS No. : 83104-87-4

规格 价格 是否有货 数量
1 mg ¥4760 In-stock
5 mg ¥14290 询价
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

生物活性

(-)-Epigallocatechin-3-(3”-O-methyl) gallate is a natural product isolated from the tea leaf, with strong antioxidative activity. (-)-Epigallocatechin-3-(3”-O-methyl) gallate has a strong cytotoxic activity for rat cancer cells[1].

分子量

472.40

Formula

C23H20O11

CAS 号

83104-87-4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

参考文献
  • [1]. Kawase M, et al. Antioxidative activity of (-)-epigallocatechin-3-(3”-O-methyl)gallate isolated from fresh tea leaf and preliminary results on its biological activity. Biosci Biotechnol Biochem. 2000 Oct;64(10):2218-20.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

AZD3514

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

AZD3514  纯度: 99.32%

AZD3514是口服的雄激素受体负调节剂,Ki为2.2 μM,可降低AR蛋白的表达。

AZD3514

AZD3514 Chemical Structure

CAS No. : 1240299-33-5

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥850 In-stock
5 mg ¥744 In-stock
10 mg ¥1302 In-stock
50 mg ¥3720 In-stock
100 mg ¥6045 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

AZD3514 相关产品

相关化合物库:

  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Anti-Cancer Compound Library
  • Clinical Compound Library
  • Transcription Factor Targeted Library

生物活性

AZD3514 is a potent and oral androgen receptor downregulator with Ki of 2.2 μM and has ability of reducing AR protein expression. IC50 Value: 2.2 uM (Ki) Target: androgen receptor AZD3514 binds to the AR ligand binding domain and has selectivity for binding to AR over other nuclear hormone receptors [1]. in vitro: AZD3514 inhibits cell growth in prostate cancer cells expressing wild-type (VCaP) and mutated (T877A) AR (LNCaP), but is inactive in AR-negative prostate cancer cells, indicating a dependency on AR for efficacy [2]. in vivo: We assessed activity initially in the Hershberger castrated rat assay in which oral dosing of AZD3514 (100mg/kg once-daily for 7 days) significantly inhibited testosterone-induced growth of sexual accessory organs [2]. Clinical trial: Open-label Prostate Cancer Study. Phase 1

Clinical Trial

分子量

519.56

Formula

C25H32F3N7O2

CAS 号

1240299-33-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 100 mg/mL (192.47 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.9247 mL 9.6235 mL 19.2471 mL
5 mM 0.3849 mL 1.9247 mL 3.8494 mL
10 mM 0.1925 mL 0.9624 mL 1.9247 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (4.81 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.81 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (4.81 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.81 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (4.81 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.81 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Bradbury RH, et al. Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer. Bioorg Med Chem Lett. 2013 Apr 1;23(7):1945-8.

    [2]. Sarah A Loddick, Rob Bradbury, Nicola Broadbent. Abstract 3848: Preclinical profile of AZD3514: A small molecule-targeting androgen receptor function with a novel mechanism of action and the potential to treat castration-resistant prostate cancer. Cancer

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

去羟加利果酸对照品

去羟加利果酸对照品

  【编号】:SPR00598

  【产品名称】:去羟加利果酸对照品

  【规格】:10mg

  【用途】:

  去羟加利果酸对照品

  编号:SPR00598
  英文名称:Esculentic acid
  CAS No.:103974-74-9
  分 子 式:C30H48O5
  分 子 量:488.709
  类别:上海金畔生物科技有限公司,天然提取物
  作为标准品,对照品或者供研究用,不能直接用于人体。

GSK-J4

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

GSK-J4  纯度: 99.64%

GSK-J4 是一种有效的 H3K27me3/me2 去甲基化酶 JMJD3/KDM6BUTX/KDM6A 双抑制剂,IC50 分别为 8.6 μM 和 6.6 μM。GSK-J4 抑制 LPS 诱导的人原代巨噬细胞产生 TNF-α,IC50 值为 9 μM。GSK-J4 是 GSK-J1 的细胞通透性前药。GSK-J4 诱导内质网应激相关的细胞凋亡 (apoptosis)。

GSK-J4

GSK-J4 Chemical Structure

CAS No. : 1373423-53-0

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥1320 In-stock
10 mg ¥1200 In-stock
50 mg ¥4500 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

GSK-J4 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Epigenetics Compound Library
  • Histone Modification Research Compound Library
  • Anti-Cancer Compound Library
  • Diabetes Related Compound Library
  • Endoplasmic Reticulum Stress Compound Library
  • Chemical Probe Library

生物活性

GSK-J4 is a potent dual inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A with IC50s of 8.6 and 6.6 μM, respectively. GSK-J4 inhibits LPS-induced TNF-α production in human primary macrophages with an IC50 of 9 μM. GSK J4 is a cell permeable prodrug of GSK-J1[1][2][3]. GSK-J4 induces endoplasmic reticulum stress-related apoptosis[4].

IC50 & Target

IC50: 8.6 µM (JMJD3/KDM6B), 6.6 µM (UTX/KDM6A)[6]

体外研究
(In Vitro)

GSK-J4 has cellular activity in Flag-JMJD3-transfected HeLa cells, in which GSK-J4 prevents the JMJD3-induced loss of nuclear H3K27me3 immunostaining. Administration of GSK-J4 increases total nuclear H3K27me3 levels in untransfected cells. GSK-J4 significantly reduces the expression of 16 of 34 LPS-driven cytokines, including tumour-necrosis factor-α (TNF-α)[1].
GSK-J4 (5 μM; 48 hours) causes a more than 3-fold increase in mouse podocyte H3K27me3 content. H3K27me3 levels in cultured podocytes, GSK-J4 reduces Jagged-1 mRNA and Jagged-1 protein levels. Correspondingly, when exposed podocytes to the inducer of dedifferentiation TGF-β1, pretreatment with GSK-J4 preventes both the increase in intracellular N1-ICD levels and the increase in α-SMA and the decrease in podocin mRNA levels[2].
GSK-J4 (10, 25 nM) acts upon DCs promoting the differentiation of Treg cells, improving Treg stability and suppressive capacities, without affecting the differentiation of Th1 and Th17 cells[3].
GSK-J4 inhibits JMJD3 expression that is induced by TGF-β1[4].
GSK-J4 inhibits H3K4 demethylation at Xist, Nodal, and HoxC13 in female embryonic stem cells[5].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

GSK-J4 Hydrochloride (10 mg/kg; i.p.; thrice-weekly for 10 weeks) attenuates the development of kidney disease in diabetic mice[2].
GSK-J4 (0.5 mg/kg, i.p.) significantly reduces the severity and delays the onset of the disease of the mouse model of experimental autoimmune encephalomyelitis[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Eight-week-old male db/m and db/db mice[2]
Dosage: 10 mg/kg
Administration: i.p.; thrice-weekly for 10 weeks
Result: Attenuated the development of kidney disease in diabetic mice.

分子量

417.50

Formula

C24H27N5O2

CAS 号

1373423-53-0

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 36 mg/mL (86.23 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.3952 mL 11.9760 mL 23.9521 mL
5 mM 0.4790 mL 2.3952 mL 4.7904 mL
10 mM 0.2395 mL 1.1976 mL 2.3952 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (4.98 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.98 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (4.98 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.98 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (4.98 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.98 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Kruidenier L, et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature. 2012 Aug 16;488(7411):404-8.

    [2]. Majumder S, et al. Shifts in podocyte histone H3K27me3 regulate mouse and human glomerular disease. J Clin Invest. 2018 Jan 2;128(1):483-499.

    [3]. Donas C, et al. The histone demethylase inhibitor GSK-J4 limits inflammation through the induction of a tolerogenic phenotype on DCs. J Autoimmun. 2016 Dec;75:105-117.

    [4]. Yapp C, et al. H3K27me3 demethylases regulate in vitro chondrogenesis and chondrocyte activity in osteoarthritis. Arthritis Res Ther. 2016 Jul 7;18(1):158

    [5]. Kamikawa YF, et al. Histone demethylation maintains Prdm14 and Tsix expression and represses xIst in embryonic stem cells. PLoS One. 2015 May 20;10(5):e0125626

    [6]. Heinemann B, et al. Inhibition of demethylases by GSK-J1/J4. Nature. 2014 Oct 2;514(7520):E1-2

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Silvestrol aglycone (enantiomer)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Silvestrol aglycone (enantiomer)  纯度: 99.10%

Silvestrol aglycone enantiomer 是 Silvestrol 的糖苷配基对映体,是一种环戊苯并呋喃核酚。

Silvestrol aglycone (enantiomer)

Silvestrol aglycone (enantiomer) Chemical Structure

CAS No. : 1112993-18-6

规格 价格 是否有货 数量
5 mg ¥9500 In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

Silvestrol aglycone (enantiomer) 相关产品

相关化合物库:

  • Bioactive Compound Library Plus

生物活性

Silvestrol aglycone enantiomer is a cyclopenta benzofuran core phenol[1].

分子量

478.49

Formula

C27H26O8

CAS 号

1112993-18-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 114 mg/mL (238.25 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.0899 mL 10.4495 mL 20.8991 mL
5 mM 0.4180 mL 2.0899 mL 4.1798 mL
10 mM 0.2090 mL 1.0450 mL 2.0899 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 7.5 mg/mL (15.67 mM); Clear solution

    此方案可获得 ≥ 7.5 mg/mL (15.67 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 75.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 7.5 mg/mL (15.67 mM); Clear solution

    此方案可获得 ≥ 7.5 mg/mL (15.67 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 75.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 7.5 mg/mL (15.67 mM); Clear solution

    此方案可获得 ≥ 7.5 mg/mL (15.67 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 75.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献
  • [1]. Adams TE, et al. Total synthesis of the potent anticancer Aglaia metabolites (-)-silvestrol and (-)-episilvestrol and the active analogue (-)-4′-desmethoxyepisilvestrol. J Am Chem Soc. 2009 Feb 4;131(4):1607-16.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Voxtalisib(Synonyms: XL765; SAR245409)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Voxtalisib (Synonyms: XL765; SAR245409) 纯度: 99.46%

Voxtalisib (XL765) 是一种有效的 PI3K 抑制剂,抑制p110αp110βp110γp110δIC50 分别为 39, 113, 9 和 43 nM,也抑制 DNA-PK (IC50=150 nM) 和 mTOR (IC50=157 nM)。Voxtalisib (XL765) 抑制 mTORC1mTORC2IC50s 分别为 160 和 910 nM。

Voxtalisib(Synonyms: XL765;  SAR245409)

Voxtalisib Chemical Structure

CAS No. : 934493-76-2

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥1238 In-stock
2 mg ¥833 In-stock
5 mg ¥1250 In-stock
10 mg ¥1950 In-stock
25 mg ¥3950 In-stock
50 mg ¥6950 In-stock
100 mg ¥12000 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Voxtalisib 相关产品

相关化合物库:

  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Kinase Inhibitor Library
  • PI3K/Akt/mTOR Compound Library
  • Stem Cell Signaling Compound Library
  • Anti-Cancer Compound Library
  • Clinical Compound Library
  • Autophagy Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Antioxidants Compound Library
  • Differentiation Inducing Compound Library
  • Reprogramming Compound Library
  • Oxygen Sensing Compound Library
  • Anti-COVID-19 Compound Library
  • Glycolysis Compound Library
  • Cytoskeleton Compound Library
  • Glutamine Metabolism Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Cancer Metabolism Compound Library
  • Angiogenesis Related Compound Library
  • Lipid Metabolism Compound Library
  • Glucose Metabolism Compound Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

Voxtalisib (XL765) is a potent PI3K inhibitor, which has a similar activity toward class I PI3K (IC50s=39, 113, 9 and 43 nM for p110α, p110β, p110γ and p110δ, respectively), also inhibits DNA-PK (IC50=150 nM) and mTOR (IC50=157 nM). Voxtalisib (XL765) inhibits mTORC1 and mTORC2 with IC50s of 160 and 910 nM, respectively.

IC50 & Target

p110α

39 nM (IC50)

p110β

113 nM (IC50)

p110δ

43 nM (IC50)

p110γ

9 nM (IC50)

mTOR

157 nM (IC50)

mTORC1

160 nM (IC50)

mTORC2

910 nM (IC50)

DNA-PK

150 nM (IC50)

体外研究
(In Vitro)

Voxtalisib (XL765) displays potent inhibitory activity against class I PI3K isoforms p110α, p110β, p110δ, and p120γ, with IC50s of 39, 110, 43, and 9 nM, respectively. The IC50 value for inhibition of PI3Kα by Voxtalisib is determined at various concentrations of ATP, revealing Voxtalisib be an ATP-competitive inhibitor with an equilibrium inhibition constant (Ki) value of 13 nM. Voxtalisib also inhibits mTOR (IC50s of 160 and 910 nM for mTORC1 and mTORC2, respectively) in an immune-complex kinase assay and the PI3K-related kinase DNA-PK (IC50 value of 150 nM). In contrast, Voxtalisib (XL765) has relatively weak inhibitory activity toward the class III PI3K vacuolar sorting protein 34 (VPS34; IC50 value of ~9.1 μM). Consistent with its inhibitory activity against purified PI3K proteins, SAR245409 inhibits EGF-induced PIP3 production in PC-3 and MCF7 cells with IC50s of 290 and 170 nM, respectively. The ability of Voxtalisib to inhibit phosphorylation of key signaling proteins downstream of PI3K is examined by assessing its effects on EGF-stimulated phosphorylation of AKT and on nonstimulated phosphorylation of S6 in PC-3 cells by cell-based ELISA. Voxtalisib inhibits these activities with IC50s of 250 and 120 nM, respectively. In MCF7 and PC-3 cells, Voxtalisib inhibits proliferation (monitored by BrdUrd incorporation) with IC50s of 1,070 and 1,840 nM, respectively. To further characterize the effects of Voxtalisib on tumor cell growth, an assay monitoring the anchorage-independent growth of PC-3 and MCF7 cells in soft agar over a 14-day period is used. SAR245409 inhibits colony growth with an IC50 value of 270 nM in PC-3 cells and 230 nM in MCF7 cells[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Oral administration of Voxtalisib (XL765) causes a dose-dependent decrease of phosphorylation of AKT, p70S6K, and S6 in the tumors, reaching a maximum of 84% inhibition of S6 phosphorylation at 30 mg/kg at 4 hours. The dose-response relationships derive from the 4 hours time point predict 50% inhibition of AKT, p70S6K, and S6 phosphorylation to occur at doses of 19 mg/kg (pAKTT308 and pAKTS473), 51 mg/kg (p-p70S6K), and 18 mg/kg (pS6). Inhibition of AKT, p70S6K, and S6 phosphorylation in MCF7 tumors following a 30 mg/kg dose of Voxtalisib is maximal at 4 hours, reaching 61% to 84%; however, the level of inhibition decreases to 0% to 42% by 24 hours, and minimal or no inhibition is evident by 48 hours. Following a 100 mg/kg dose of Voxtalisib, inhibition is also maximal at 4 hours (52%-75%)[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

270.29

Formula

C13H14N6O

CAS 号

934493-76-2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 10 mg/mL (37.00 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.6997 mL 18.4986 mL 36.9973 mL
5 mM 0.7399 mL 3.6997 mL 7.3995 mL
10 mM 0.3700 mL 1.8499 mL 3.6997 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 1 mg/mL (3.70 mM); Clear solution

    此方案可获得 ≥ 1 mg/mL (3.70 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 1 mg/mL (3.70 mM); Clear solution

    此方案可获得 ≥ 1 mg/mL (3.70 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 1 mg/mL (3.70 mM); Clear solution

    此方案可获得 ≥ 1 mg/mL (3.70 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Garcia-Echeverria C, et al. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 2008 Sep 18;27(41):5511-26.

    [2]. Yu P, et al. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway. Mol Cancer Ther. 2014 May;13(5):1078-91.

Cell Assay
[2]

Cellular proliferation is assessed using the Cell Proliferation ELISA, Bromodeoxyuridine Chemiluminescence Kit. Cytotoxicity is assessed using the ATP Bioluminescence Assay as follows: PC-3, MCF7, A549, LS174T, MDA-MB-468, U87-MG, and OVCAR-3 cells are plated at densities of 7×103, 1.5×104, 6×103, 7×103, 7×103, 6×103, 1.5×104 cells per well, respectively, onto 96-well microtiter plates in culture medium, incubated at 37°C, 5% CO2 for 18 hours, and then treated with a serial dilution of compound in medium containing a final concentration of 0.3% DMSO. Triplicate wells are used for each compound concentration. Control wells receive 0.3% DMSO in media. Cultures are incubated at 37°C, 5% CO2 for an additional 24 hours and cells are then assayed for viability using the ViaLight HS Kit[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[2]

Mice[2]
In vivo efficacy studies are performed in athymic nude mice. Tumor cells are cultured in DMEM supplemented with 10% FBS (20% for PC-3 and OVCAR-3 cells), Penicillin-Streptomycin, and nonessential amino acids at 37°C in a humidified 5% CO2 atmosphere. On day 0, cells are harvested by brief trypsinization, and 1 to 5×106 cells in 0.1 mL ice-cold Hanks Balanced Salt Solution are implanted subcutaneously (OVCAR-3) or intradermally (MCF7 and U-87 MG) into the hind flank of female athymic nude mice. In the case of the MCF7 model, an estrogen pellet (IRA) is implanted subcutaneously at the nape of neck at the time of tumor cell implantation. A total of 3×106 PC-3 cells are similarly harvested and implanted subcutaneously into the hind-flank of 5- to 8-week-old male nude mice. Tumor growth is monitored weekly with calipers until staging and dose initiation. During the dosing period, body and tumor weights are assessed. Voxtalisib (XL-765) is formulated in sterile water/10 mM HCl or water and administered at the indicated doses and regimens by oral gavage at a dose volume of 10 mL/kg.

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Garcia-Echeverria C, et al. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 2008 Sep 18;27(41):5511-26.

    [2]. Yu P, et al. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway. Mol Cancer Ther. 2014 May;13(5):1078-91.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

3L超声波清洗器KQ2200B/KQ2200E/KQ2200V

【简单介绍】

3L超声波清洗器KQ2200B/KQ2200E/KQ2200V主要特点:
经典机械式控制,操作简单方便

清洗机降音盖、清洗槽均采用优质不锈钢

“V型”系列清洗机密封性好,并具有隔音、隔热效果

清洗机电路具有自动扫频功能,能产生连续脉冲射流,使清洗效果更明显,工作更稳定

清洗机电路及器件升级并匹配,电功转换率高、无功损耗低

可选单种超声频率有20KHz、25KHz、28KHz、33KHz、

【详细说明】

3L超声波清洗器KQ2200B/KQ2200E/KQ2200V

产品简述:

台式超声波清洗机,采用电路自动扫频技术,使清洗机工作电功率转换更高,无功损耗更低,大大提升了清洗的洁净度,可满足各行业实验室的超声清洗等需求。

       系列产品可用于:超声波清洗、乳化、混匀、提取、分散、消泡、脱气、细胞粉碎、催化反应等 

3L超声波清洗器KQ2200B/KQ2200E/KQ2200V

技术参数:

型号:KQ2200 外形尺寸:260*160*270mm 内槽尺寸:230*140*100mm 容量:3L
标准超声频率:40KHz 超声频率可选择替换 频率转换时间可调:— 超声功率:100W
超声功率可调范围:— 水位显示:— 加热功率:—  
制冷功率:— 温度设定范围:— 工作时间可调:1-20min 溶液过滤:—
其他配置:清洗网篮、手控进排水、220V/50Hz电源
型号:KQ2200B 外形尺寸:260*160*270mm 内槽尺寸:230*140*100mm 容量:3L
标准超声频率:40KHz 超声频率可选择替换 频率转换时间可调:— 超声功率:100W
超声功率可调范围:— 水位显示:— 加热功率:200W  
制冷功率:— 温度设定范围:室温-80℃ 工作时间可调:1-20min 溶液过滤:—
其他配置:清洗网篮、手控进排水、220V/50Hz电源
型号:KQ2200E 外形尺寸:260*160*285mm 内槽尺寸:230*140*100mm 容量:3L
标准超声频率:40KHz 超声频率可选择替换 频率转换时间可调:— 超声功率:100W
超声功率可调范围:— 水位显示:— 加热功率:200W  
制冷功率:— 温度设定范围:室温-80℃ 工作时间可调:1-20min 溶液过滤:—
其他配置:清洗网篮、降音盖、手控进排水、220V/50Hz电源
型号:KQ2200V 外形尺寸:345*250*315mm 内槽尺寸:230*140*130mm 容量:4L
标准超声频率:40KHz 超声频率可选择替换 频率转换时间可调:— 超声功率:100W
超声功率可调范围:— 水位显示:— 加热功率:400W  
制冷功率:— 温度设定范围:室温-80℃ 工作时间可调:1-20min 溶液过滤:—
其他配置:清洗网篮、降音盖、手控进排水、220V/50Hz电源
 

相关产品:

昆山舒美KQ116超声波清洗器

容量(L):0.6, 超声频率(KHz):40, 超声功率:20W

 

昆山舒美KQ118超声波清洗器

容量(L):0.6, 超声频率(KHz):40, 超声功率:70W

 

昆山舒美KQ218超声波清洗器

容量(L):0.6, 超声频率(KHz):40 超声功率:100W

 

昆山舒美KQ-50超声波清洗器

容量(L):1.5, 超声频率(KHz):40, 超声功率:50W

 

昆山舒美KQ-50B超声波清洗器

容量(L):2, 超声频率(KHz):40, 超声功率:50W

无盖

昆山舒美KQ-50E超声波清洗器

容量(L):2, 超声频率(KHz):40, 超声功率50W

 

昆山舒美KQ2200超声波清洗器

容量(L):3, 超声频率(KHz):40, 超声功率100W

 

昆山舒美KQ2200B超声波清洗器

容量(L):3, 超声频率(KHz):40, 超声功率:100W

 

昆山舒美KQ2200E超声波清洗器

容量(L):3, 超声频率(KHz):40, 超声功率:100W

 

昆山舒美KQ2200V超声波清洗器

容量(L):4, 超声频率(KHz):40, 超声功率:100W

 

昆山舒美KQ-100超声波清洗器

容量(L):4, 超声频率(KHz):40, 超声功率:100W

 

昆山舒美KQ-100B超声波清洗器

容量(L):4, 超声频率(KHz):40, 超声功率:100W

 

昆山舒美KQ-100E超声波清洗器

容量(L):4, 超声频率(KHz):40, 超声功率:100W

 

昆山舒美KQ-100V超声波清洗器

容量(L):5.8, 超声频率(KHz):40, 超声功率:100W

 

昆山舒美KQ3200超声波清洗器

容量(L):6, 超声频率(KHz):40, 超声功率:150W

 

昆山舒美KQ3200B超声波清洗器

容量(L):6, 超声频率(KHz):40, 超声功率:150W

无盖 

昆山舒美KQ3200E超声波清洗器

容量(L):6, 超声频率(KHz):40, 超声功率:150W

 

昆山舒美KQ3200V超声波清洗器

容量(L):8, 超声频率(KHz):40, 超声功率:150W

 

昆山舒美KQ5200超声波清洗器

容量(L):10, 超声频率(KHz):40, 超声功率:200W

 

昆山舒美KQ5200B超声波清洗器

容量(L):10, 超声频率(KHz):40, 超声功率:200W

无盖

昆山舒美KQ5200E超声波清洗器

容量(L):10, 超声频率(KHz):40, 超声功率:200W

 

昆山舒美KQ5200V超声波清洗器

容量(L):13, 超声频率(KHz):40, 超声功率:200W

 

昆山舒美KQ-250超声波清洗器

容量(L):10, 超声频率(KHz):40, 超声功率:250W

 

昆山舒美KQ-250B超声波清洗器

容量(L):10, 超声频率(KHz):40, 超声功率:250W

无盖

昆山舒美KQ-250E超声波清洗器

容量(L):10, 超声频率(KHz):40, 超声功率:250W

 

昆山舒美KQ-250V超声波清洗器

容量(L):13, 超声频率(KHz):40, 超声功率:250W

 

昆山舒美KQ-300超声波清洗器

容量(L):10, 超声频率(KHz):40, 超声功率:300W

无网架

昆山舒美KQ-300B超声波清洗器

容量(L):10, 超声频率(KHz):40, 超声功率:300W

无盖

昆山舒美KQ-300E超声波清洗器

容量(L):10, 超声频率(KHz):40, 超声功率:300W

 

昆山舒美KQ-300V超声波清洗器

容量(L):13, 超声频率(KHz):40, 超声功率:300W

 

昆山舒美KQ-500超声波清洗器

容量(L):22.5, 超声频率(KHz):40, 超声功率:500W

 

昆山舒美KQ-500B超声波清洗器

容量(L):22.5, 超声频率(KHz):40, 超声功率:500W

无盖

昆山舒美KQ-500E超声波清洗器

容量(L):22.5, 超声频率(KHz):40, 超声功率:500W

 

昆山舒美KQ-500V超声波清洗器

容量(L):27, 超声频率(KHz):40, 超声功率:500W

 

昆山舒美KQ-600超声波清洗器

容量(L):22.5, 超声频率(KHz):40, 超声功率:600W

 

昆山舒美KQ-600B超声波清洗器

容量(L):22.5, 超声频率(KHz):40, 超声功率:600W

无盖

昆山舒美KQ-600E超声波清洗器

容量(L):22.5, 超声频率(KHz):40, 超声功率:600W

 

昆山舒美KQ-600V超声波清洗器

容量(L):27, 超声频率(KHz):40, 超声功率:600W

 

昆山舒美KQ-700超声波清洗器

容量(L):22.5, 超声频率(KHz):40, 超声功率:700W

 

 

型号:KQ2200 外形尺寸:260*160*270mm 内槽尺寸:230*140*100mm 容量:3L
标准超声频率:40KHz 超声频率可选择替换 频率转换时间可调:— 超声功率:100W
超声功率可调范围:— 水位显示:— 加热功率:—  
制冷功率:— 温度设定范围:— 工作时间可调:1-20min 溶液过滤:—
其他配置:清洗网篮、手控进排水、220V/50Hz电源
型号:KQ2200B 外形尺寸:260*160*270mm 内槽尺寸:230*140*100mm 容量:3L
标准超声频率:40KHz 超声频率可选择替换 频率转换时间可调:— 超声功率:100W
超声功率可调范围:— 水位显示:— 加热功率:200W  
制冷功率:— 温度设定范围:室温-80℃ 工作时间可调:1-20min 溶液过滤:—
其他配置:清洗网篮、手控进排水、220V/50Hz电源
型号:KQ2200E 外形尺寸:260*160*285mm 内槽尺寸:230*140*100mm 容量:3L
标准超声频率:40KHz 超声频率可选择替换 频率转换时间可调:— 超声功率:100W
超声功率可调范围:— 水位显示:— 加热功率:200W  
制冷功率:— 温度设定范围:室温-80℃ 工作时间可调:1-20min 溶液过滤:—
其他配置:清洗网篮、降音盖、手控进排水、220V/50Hz电源
型号:KQ2200V 外形尺寸:345*250*315mm 内槽尺寸:230*140*130mm 容量:4L
标准超声频率:40KHz 超声频率可选择替换 频率转换时间可调:— 超声功率:100W
超声功率可调范围:— 水位显示:— 加热功率:400W  
制冷功率:— 温度设定范围:室温-80℃ 工作时间可调:1-20min 溶液过滤:—
其他配置:清洗网篮、降音盖、手控进排水、220V/50Hz电源
 

ent-3-Oxokauran-17-oic acid对照品

ent-3-Oxokauran-17-oic acid对照品

  【编号】:SPR00581

  【产品名称】:ent-3-Oxokauran-17-oic acid对照品

  【规格】:10mg

  【用途】:

  ent-3-Oxokauran-17-oic acid对照品

  编号:SPR00581
  英文名称:ent-3-Oxokauran-17-oic acid
  CAS No.:151561-88-5
  分 子 式:C20H30O3
  分 子 量:318.457
  类别:上海金畔生物科技有限公司,天然提取物
  作为标准品,对照品或者供研究用,不能直接用于人体。